Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) Price Target at $326.42

Shares of United Therapeutics Co. (NASDAQ:UTHR) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $331.73.

A number of brokerages recently commented on UTHR. Wells Fargo & Company raised their target price on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Bank of America decreased their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd.

Insider Buying and Selling

In related news, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at $569,362.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $338.61, for a total transaction of $1,218,996.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,019.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the transaction, the director now owns 1,750 shares in the company, valued at approximately $569,362.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,644 shares of company stock worth $31,558,715. 12.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently bought and sold shares of the business. V Square Quantitative Management LLC purchased a new stake in United Therapeutics during the 2nd quarter worth $30,000. Rise Advisors LLC acquired a new stake in shares of United Therapeutics during the first quarter valued at about $32,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $33,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth about $43,000. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 117 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $321.96 on Friday. The business’s fifty day simple moving average is $310.44 and its 200-day simple moving average is $263.02. The company has a quick ratio of 3.64, a current ratio of 4.35 and a debt-to-equity ratio of 0.02. The firm has a market cap of $14.28 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $343.98.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same period in the previous year, the company earned $5.24 EPS. The company’s quarterly revenue was up 19.8% compared to the same quarter last year. Equities analysts forecast that United Therapeutics will post 25.4 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.